JP2023518397A5 - - Google Patents
Info
- Publication number
- JP2023518397A5 JP2023518397A5 JP2022555913A JP2022555913A JP2023518397A5 JP 2023518397 A5 JP2023518397 A5 JP 2023518397A5 JP 2022555913 A JP2022555913 A JP 2022555913A JP 2022555913 A JP2022555913 A JP 2022555913A JP 2023518397 A5 JP2023518397 A5 JP 2023518397A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- hepatitis
- inhibitor
- use according
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991292P | 2020-03-18 | 2020-03-18 | |
| US62/991,292 | 2020-03-18 | ||
| US202063069667P | 2020-08-24 | 2020-08-24 | |
| US63/069,667 | 2020-08-24 | ||
| US202163140735P | 2021-01-22 | 2021-01-22 | |
| US63/140,735 | 2021-01-22 | ||
| PCT/US2021/022786 WO2021188688A1 (en) | 2020-03-18 | 2021-03-17 | Farnesoid x receptor agonists for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026066715A Division JP2026133383A (ja) | 2020-03-18 | 2026-04-15 | 疾患の治療のためのファルネソイドｘ受容体アゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518397A JP2023518397A (ja) | 2023-05-01 |
| JP2023518397A5 true JP2023518397A5 (enExample) | 2024-03-29 |
| JP7851856B2 JP7851856B2 (ja) | 2026-04-27 |
Family
ID=77771857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555913A Active JP7851856B2 (ja) | 2020-03-18 | 2021-03-17 | 疾患の治療のためのファルネソイドｘ受容体アゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230131804A1 (enExample) |
| EP (1) | EP4121048A4 (enExample) |
| JP (1) | JP7851856B2 (enExample) |
| KR (1) | KR20220154801A (enExample) |
| CN (4) | CN120732855A (enExample) |
| AU (1) | AU2021240001A1 (enExample) |
| BR (1) | BR112022018651A2 (enExample) |
| CA (1) | CA3172205A1 (enExample) |
| IL (1) | IL296539A (enExample) |
| MX (1) | MX2022011579A (enExample) |
| TW (1) | TWI895384B (enExample) |
| WO (1) | WO2021188688A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3852748B1 (en) | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
| CN120227340A (zh) | 2020-03-18 | 2025-07-01 | 伊莱利利公司 | 法尼醇x受体激动剂的制剂 |
| JP7664278B2 (ja) * | 2020-03-18 | 2025-04-17 | オルガノボ，インク． | ファルネソイドｘ受容体アゴニストの結晶質形態 |
| CN117018000B (zh) * | 2023-08-29 | 2025-01-28 | 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) | 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用 |
| WO2026149323A1 (en) * | 2025-01-07 | 2026-07-16 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists |
| CN120837611B (zh) * | 2025-09-22 | 2025-12-16 | 吉林大学 | 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| AU2016233579A1 (en) * | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| WO2017049176A1 (en) * | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3350165B1 (en) | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3350166A4 (en) * | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| AU2018236275B2 (en) * | 2017-03-15 | 2022-05-12 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| DK3596053T3 (da) * | 2017-03-15 | 2023-09-25 | Organovo Inc | Farnesoid-x-receptoragonister og anvendelser deraf |
| EP3852748B1 (en) * | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
-
2021
- 2021-03-17 KR KR1020227036071A patent/KR20220154801A/ko active Pending
- 2021-03-17 CN CN202511190792.8A patent/CN120732855A/zh active Pending
- 2021-03-17 JP JP2022555913A patent/JP7851856B2/ja active Active
- 2021-03-17 US US17/906,580 patent/US20230131804A1/en active Pending
- 2021-03-17 MX MX2022011579A patent/MX2022011579A/es unknown
- 2021-03-17 CN CN202180036461.2A patent/CN115666559A/zh active Pending
- 2021-03-17 TW TW110109622A patent/TWI895384B/zh active
- 2021-03-17 IL IL296539A patent/IL296539A/en unknown
- 2021-03-17 CN CN202511190799.XA patent/CN120732856A/zh active Pending
- 2021-03-17 BR BR112022018651A patent/BR112022018651A2/pt unknown
- 2021-03-17 EP EP21772019.2A patent/EP4121048A4/en active Pending
- 2021-03-17 CN CN202511190786.2A patent/CN120732854A/zh active Pending
- 2021-03-17 CA CA3172205A patent/CA3172205A1/en active Pending
- 2021-03-17 WO PCT/US2021/022786 patent/WO2021188688A1/en not_active Ceased
- 2021-03-17 AU AU2021240001A patent/AU2021240001A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504643A5 (enExample) | ||
| JP2023537285A5 (enExample) | ||
| JP2024520677A5 (enExample) | ||
| JP6941057B2 (ja) | オベチコール酸の組成物および使用方法 | |
| JP2023504647A5 (enExample) | ||
| JP2509044B2 (ja) | 胆汁酸塩を含有する胃液耐性のある経口投与用製剤 | |
| JP2023504644A5 (enExample) | ||
| JP2024500309A5 (enExample) | ||
| JP2509045B2 (ja) | 胆汁酸を含有する経口投与用の胃液耐性のある製剤 | |
| JP7697885B2 (ja) | 化合物の製剤およびそれらの使用 | |
| JP2022519370A5 (enExample) | ||
| CN102395276A (zh) | 硝唑尼特的控制释放药物剂型 | |
| JP2020514333A5 (enExample) | ||
| WO2004108161A1 (ja) | 固形製剤 | |
| AU2017210661A1 (en) | Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of SGLT | |
| JP2012518002A5 (enExample) | ||
| WO2009149056A2 (en) | Combinations of niacin and an oxicam | |
| JP2021513552A5 (enExample) | ||
| JP2023517844A (ja) | ベンズイミダゾール誘導体化合物を含有する医薬組成物 | |
| US20200148617A1 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| JP2019534330A5 (enExample) | ||
| CN115515569A (zh) | 嘧啶环己基糖皮质激素受体调节剂的制剂 | |
| CN107530287A (zh) | 药物制剂 | |
| WO2009080030A1 (en) | Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus | |
| RU2019110780A (ru) | Комбинация агонистов fxr |